Space Seed Holdings has established a new company, Regenesome Ltd, to commercialize exosome research.
Started business development to contribute to society by developing technologies in the field of exosome research, which is advancing rapidly worldwide.
Background to the establishment
Space Seed Holdings has participated in the Space Food Sphere*1 since April 2024 and has promoted research and development. In addition, through its participation in XPRIZE Healthspan*2, since May 2024, the company has been developing healthcare-related products and technology in the medical field, focusing on the analysis of exosomes.
*1 Press release on participation in the Space Food Sphere https://prtimes.jp/main/html/rd/p/000000001.000140650.html
*2 Press release announcing participation in XPRIZE Healthspan https://prtimes.jp/main/html/rd/p/000000004.000140650.html
The business concept of using the research network of Space Seed Holdings to contribute to society through the development of technology to control ageing in the world has now taken shape, leading to the establishment of a new company to proactively implement this business.
What is Exosome?
Exosomes are 40-150 nm extracellular vesicles (sEVs: small extracellular vesicles) arising from organelle endosomes, which are responsible for transporting and processing substances taken up from outside the cell, and are reported to be secreted by many cell types*3.
*3 Reference https://www.cell.com/cell/fulltext/S0092-8674(19)30212-0
Exosomes contain RNA (including mRNA, microRNA and other non-coding RNAs), DNA, lipids and proteins, and play an important role in intercellular communication in the human body. Exosomes facilitate intercellular signaling by transporting and delivering specific molecular information to other cells, thereby regulating various physiological and pathological processes.
They also regulate the progression of inflammatory reactions and immune diseases by regulating cell-to-cell interactions in the immune system and enhancing or suppressing immune responses. Exosomes released by cancer cells contribute to cancer progression and metastasis and carry factors involved in cancer cell proliferation, angiogenesis and immunosuppression.
Other properties of exosomes, such as their ability to transport growth factors and microRNAs that contribute to the repair and regeneration of damaged tissues, have also attracted attention in the field of regenerative medicine.
Mission, vision and values of Regenesome Ltd.
The corporation's philosophy is to use technological development from a biotechnological perspective to solve the challenges of the future caused by ageing, based on the following principles.
Mission
We will provide anti-ageing technology that can be applied on the ground in 2040, which will be necessary for humans to expand their living space to the Moon.
Vision
We will demonstrate anti-ageing technologies in Healthspan in 2030.
Value
・Accumulation of scientific knowledge on exosomes.
・Establishment of a network for space science practice.
・Research and development of solutions to health issues such as anti-ageing on Earth and in space.
Image of practical application of exosome diagnostic equipment.
Business activities of Regenesome Ltd.
By carrying out omics-related analyses in cultured cells in different environments and in human clinical trials, as well as by analysing exosomes in detail, we will clarify how each environment is involved in the production of exosomes and how exosomes function in the organism.
In the progress of this research, we expect to gain knowledge on how to use exosomes to inhibit ageing. Through these research and development activities, we plan to pursue the possibility of not only making new proposals in the field of space medicine, but also contributing to the advancement of medical technology utilized on Earth. Specific projects to be carried out include.
Development of supplements, foods and cosmetics utilising exosomes
Development of new products and services utilising other substances contained in cells
Intellectual property management
Consulting services relating to management, sales, research, etc.
Planning, production, operation and management of various events
Photography, planning, production and sales of photographs and videos.
Board of Directors
CEO: Kengo Suzuki
He co-founded Euglena in 2005 while studying for a master's degree at the University of Tokyo's Graduate School of Agricultural and Life Sciences; he received his PhD (Agriculture) degree in 2016 and his PhD (Medicine) degree in 2019. In addition to being the representative director of Space Seed Holdings Corporation, the parent company of Regenesome, he is a team leader at RIKEN and a specially appointed (visiting) professor at Tohoku University, where he is responsible for the company's research and development.
President and Representative Director: Zentaro Sakuma
He graduated from the University of Tokyo in 2004 with a degree in economics, worked in sales and finance at NTT DOCOMO and as head of international coordination at the Financial Services Agency. He was Executive Vice President of Unitedly Inc. from 2018, joined E-Partner Inc. in 2021 and served as director and head of corporate planning From 2024, he is a director of Space Seed Holdings Inc and was appointed as representative director, responsible for business promotion. He is a US CPA and earned an MBA from New York University.
About Space Seed Holdings
Space Seed Holdings Ltd. is working to solve social issues through the exploration of new technology themes, investment in start-ups and joint research with universities, with the mission of "turning science fiction into non-fiction". Ultimately, the company aims to work with various stakeholders to develop the technologies necessary for living in outer space. In the future, we plan to actively provide new services and products to address social issues while continuing a science-based dialogue with society based on 'science' x 'narrative', utilizing our in-house academic knowledge and networks.
Space Seed Holdings HP: https://ss-hd.co.jp/